Dan Mitchell

Sequel Venture Partners LLC (Sequel Venture Partners) is a venture capital firm founded in 1996 by Kinney Johnson, Daniel Mitchell and Thomas Washing. The firm is headquartered in Boulder, Colorado.

ViroCyt, Inc. develops life science instrumentation and assays products for the analysis of viruses and microorganisms. The company was founded in 2012 and is headquartered in Broomfield, CO.

Bolder Surgical LLC engages in the design, development, and manufacture of surgical devices. Its products include JustRight Vessel Sealing System, JustRight 5mm Stapler, and EcoSac 5mm Tissue Retrieval System. The company was founded by Russell Lindemann, Scott Drake, Dale Schmaltz, Jenifer Kennedy, Patricia Moroney Hoag, David R. Duncan, and Steve Rothenberg on January 22, 2010 and is headquartered in Louisville, CO.

Part of Inotiv, Inc., Plato BioPharma, Inc. develops preclinical drug discovery. The company is based in Westminster, CO. Plato BioPharma was acquired by Inotiv, Inc. on October 04, 2021 for $14.76 million. The company was founded in 2010 by Craig F. Plato. Craig F. Plato has been the CEO since 2010.

Skyland Analytics, Inc. provides power of manufacturing informatics software, IT systems and data analytics services. Its services include informatics, risk management and discoverant. The company was founded by Robert M. Di Scipio and is headquartered in Niwot, CO.

Replidyne, Inc. is a biopharmaceutical company focused on developing and commercializing innovative anti-infective products. The company's new drug application (NDA) for its lead product, faropenem medoxomil, has been accepted for standard review by the FDA. Faropenem medoxomil is an orally available antibiotic for the treatment of community acquired infections, such as respiratory tract infections. Other development programs include higher dose/shorter course therapy, additional ndications for adults and a pediatric formulation of faropenem medoxomil. The ompany’s pipeline also includes a topical anti-bacterial product, REP8839, hich has a novel mechanism of action for addressing the major challenge of ethicillin-resistant Staphylococcus aureus (MRSA). The company also has iscovery programs directed to the inhibition of bacterial DNA replication, which could result in therapies to treat a wide range of antibiotic-resistant bacteria. The company is headquartered in Louisville, CO